Volume 39, Issue 4, Pages (August 2010)

Slides:



Advertisements
Similar presentations
Suppl. Figure 1 miR-107 levels NormalPituitary Tumors miR-103 levels miR-125b levels miR-141 levels miR-144 levels miR-164 levels miR-145 levels miR-143.
Advertisements

Identification of a Novel Substance P–Neurokinin-1 Receptor MicroRNA-221-5p Inflammatory Network in Human Colonic Epithelial Cells  Kai Fang, Aristea.
Volume 141, Issue 5, Pages e1 (November 2011)
Volume 11, Issue 4, Pages (April 2007)
MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of Breast Cancer Cells by Targeting Sex-Determining Region Y-Box 2 Cell.
Volume 145, Issue 4, Pages e2 (October 2013)
Cell Physiol Biochem 2017;44:1867– DOI: /
Factor VII-Induced MicroRNA-135a Inhibits Autophagy and Is Associated with Poor Prognosis in Hepatocellular Carcinoma  Kuang-Tzu Huang, I-Ying Kuo, Ming-Chao.
Volume 15, Issue 6, Pages (June 2009)
Volume 145, Issue 2, Pages (August 2013)
A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
miR-133a positively regulated p53/p21 pathway.
Volume 20, Issue 2, Pages (August 2011)
Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP  Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.
A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation  Lily Mahapatra, Neal Andruska, Chengjian Mao,
Volume 55, Issue 1, Pages (July 2014)
Volume 137, Issue 2, Pages e2 (August 2009)
Volume 141, Issue 5, Pages e1 (November 2011)
Volume 23, Issue 3, Pages (April 2018)
Volume 9, Issue 6, Pages (June 2006)
Volume 145, Issue 4, Pages e2 (October 2013)
Volume 11, Issue 2, Pages (February 2007)
Volume 58, Issue 2, Pages (April 2015)
Volume 17, Issue 4, Pages (April 2010)
Volume 71, Issue 5, Pages e5 (September 2018)
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells
Revealing Global Regulatory Perturbations across Human Cancers
Volume 53, Issue 5, Pages (March 2014)
Volume 17, Issue 4, Pages (April 2010)
Volume 145, Issue 2, Pages (August 2013)
A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance  Ji-Hak.
Volume 25, Issue 3, Pages (March 2017)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
Volume 43, Issue 5, Pages (September 2011)
Volume 26, Issue 2, Pages (February 2018)
Volume 49, Issue 1, Pages (January 2013)
TNFα Signaling Exposes Latent Estrogen Receptor Binding Sites to Alter the Breast Cancer Cell Transcriptome  Hector L. Franco, Anusha Nagari, W. Lee Kraus 
Glucose-Induced β-Catenin Acetylation Enhances Wnt Signaling in Cancer
IL6-Mediated Suppression of miR-200c Directs Constitutive Activation of Inflammatory Signaling Circuit Driving Transformation and Tumorigenesis  Matjaz.
Xiaolong Wei, Hai Xu, Donald Kufe  Cancer Cell 
Shi-Yan Ng, Gireesh K. Bogu, Boon Seng Soh, Lawrence W. Stanton 
Revealing Global Regulatory Perturbations across Human Cancers
Volume 31, Issue 4, Pages (August 2008)
MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
FOXO3a Is Activated in Response to Hypoxic Stress and Inhibits HIF1-Induced Apoptosis via Regulation of CITED2  Walbert J. Bakker, Isaac S. Harris, Tak.
Volume 147, Issue 6, Pages (December 2011)
Promotion Effects of miR-375 on the Osteogenic Differentiation of Human Adipose- Derived Mesenchymal Stem Cells  Si Chen, Yunfei Zheng, Shan Zhang, Lingfei.
Volume 15, Issue 4, Pages (April 2009)
P. Harding, L. Balasubramanian, J. Swegan, A. Stevens, W.F. Glass 
Spatial and Temporal Recruitment of Androgen Receptor and Its Coactivators Involves Chromosomal Looping and Polymerase Tracking  Qianben Wang, Jason S.
Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro- inflammatory “FADDosome” Complex upon TRAIL Stimulation  Conor M. Henry, Seamus.
Volume 85, Issue 3, Pages (March 2014)
Volume 18, Issue 6, Pages (December 2015)
Volume 36, Issue 2, Pages (October 2009)
Volume 35, Issue 1, Pages (July 2009)
An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation  Dimitrios Iliopoulos, Heather A. Hirsch,
Volume 8, Issue 4, Pages (October 2005)
Volume 56, Issue 6, Pages (December 2014)
Volume 15, Issue 12, Pages (June 2016)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504
Volume 125, Issue 4, Pages (May 2006)
Fan Yang, Huafeng Zhang, Yide Mei, Mian Wu  Molecular Cell 
Shipra Das, Olga Anczuków, Martin Akerman, Adrian R. Krainer 
Volume 58, Issue 2, Pages (April 2015)
Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κB  Wei-Chien Huang, Tsai-Kai Ju, Mien-Chie.
Volume 55, Issue 1, Pages (July 2014)
Volume 53, Issue 5, Pages (March 2014)
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
Presentation transcript:

Volume 39, Issue 4, Pages 493-506 (August 2010) STAT3 Activation of miR-21 and miR-181b-1 via PTEN and CYLD Are Part of the Epigenetic Switch Linking Inflammation to Cancer  Dimitrios Iliopoulos, Savina A. Jaeger, Heather A. Hirsch, Martha L. Bulyk, Kevin Struhl  Molecular Cell  Volume 39, Issue 4, Pages 493-506 (August 2010) DOI: 10.1016/j.molcel.2010.07.023 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 MicroRNA Dynamics during ER-Src Cellular Transformation (A) Differentially expressed microRNAs between transformed (TAM 36 hr) and untransformed (0 hr) MCF10A ER-Src cells. (B) Heatmap representation of differentially expressed microRNAs in different time points (1, 2, 4, 8, 12, 16, 24, and 36 hr) during ER-Src transformation. Upregulated microRNAs are shown in red, while downregulated microRNAs are shown in green. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 2 MicroRNAs Important for ER-Src Transformation (A) Strategy for identifying microRNAs regulating ER-Src transformation. (B) Heatmap representation of transformation efficiency (percent transformed cells as assayed by cell morphology) after transfection of microRNAs or antisense microRNAs in ER-Src cells. (C and D) Soft agar colony assay (C) and invasion assay (D) in ER-Src cells transfected with sense or antisense microRNAs. Experiments performed in triplicate and data are shown as mean ±SD. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 3 STAT3 and Myc Are Important Regulators of Transformation (A) Lever algorithm analysis to identify transcription factor binding site motifs overrepresented in promoter areas of differentially expressed microRNAs. Motifs with AUC score higher than 0.7 and z-score higher than 2 are considered statistically significant (red color), with STAT3 and Myc indicated. (B) Pairs of motifs (connected by lines) of TFs that are differentially regulated (upregulated in red and downregulated in blue) during transformation and overrepresented in microRNA promoters. (C) STAT3 and Myc mRNA expression levels in ER-Src cells during transformation. (D) Soft agar colony assay (mean ±SD) in TAM-treated (36 hr) cells transfected with siRNAs against STAT3, Myc, or control. (E) Soft agar colony assay (mean ±SD) in transformed ER-Src cells (for 10 days) transfected with siRNAs against STAT3, Myc, or control. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 4 STAT3 and Myc-Regulated MicroRNAs during ER-Src Transformation (A) STAT3 occupancy (fold enrichment) at the indicated miR loci in cells that were or were not treated with TAM, as determined by ChIP. (B) MicroRNA expression levels in TAM-treated ER-Src cells transfected in the presence of STAT3 inhibitors (siSTAT3#2 or 8 μM JSI-124). (C) MicroRNA expression levels in MCF-10A cells treated with 50 ng/ml IL-6. (D) Soft agar colony assay in MCF10A-IL-6 transformed cells transfected with the indicated antisense microRNAs. (E) Myc occupancy (fold enrichment) at the indicated miR loci that were or were not treated with TAM. (F) MicroRNA expression levels in TAM-treated ER-Src cells transfected with siRNA negative control or siMyc. In all experiments, data are presented as mean ±SD of three independent experiments. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 5 miR-21 and miR-181b-1 Induce Transformation of MCF-10A Cells (A) Colony formation assay of MCF-10A cells treated with miR-21, miR-181b-1, Lin28b, BAY-117082 (5 μM), or siRNA against Lin28B. (B) Cells treated with miR-21 or miR-181b-1 were propagated for 10 or 30 days and tested for cell morphology and colony formation. (C) NF-κB activity in MCF-10A cells treated with as-miR-NC, as-miR-21, as-miR-181b-1, or BAY-117082. The data are presented as mean ±SD of three independent experiments. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 6 miR-181b-1 Regulates CYLD Expression during ER-Src Transformation (A) Sequence complementarity between miR-181b-1 and the 3′ UTR of CYLD gene. (B) miR-181b-1 and CYLD mRNA expression levels at the indicated times during ER-Src transformation. (C) Luciferase activity of a reporter containing the 3′ UTR of CYLD 24 hr after transfection with miR-181b-1 or miR negative control. (D) CYLD mRNA levels after treatment with miR-181b-1 or miR negative control. (E) CYLD protein levels after treatment with miR-181b-1 or miR negative control. (F) CYLD mRNA levels after treatment with as-miR-181b-1 or as-miR-NC. (G) NF-κB activity (ELISA assay) in ER-Src cells untreated (NT) or treated with as-miR-181b-1, si-CYLD, or as-miR-NC. (H) IL-6 production (ELISA assay) in ER-Src cells treated with as-miR-181b-1, si-CYLD, or as-miR-NC. (I–K) Number of colonies (I), NF-κB activity assessed by ELISA assay (J), and IL-6 luciferase activity (K) in ER-Src cells treated with two different siRNAs against CYLD. The data are presented as mean ±SD of three independent experiments. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 7 STAT3-Regulated MicroRNAs in Cancer Cells, Xenografts, and Cancer Patients (A) Colony formation assay in colon (HCT-116, HT-29), prostate (PC3), lung (A549), cervical (HeLa), hepatocellular (Hep3B), and pancreatic (Panc1) cancer cell lines treated with antisense microRNA negative control, antisense-miR-21, antisense-miR-181b-1, or their combination. The data are presented as mean ±SD of three independent experiments. (B) Tumor growth (mean ±SD) of ER-Src cells after i.p. treatment (days 10, 15, 20, and 25) with Ab-IgG, Ab-IL-6, siRNA negative control, siRNA against STAT3, antisense miR-NC, antisense-miR-21, and/or antisense-miR-181b-1. (C) miR-21 and miR-181b-1 expression levels from tumors derived from the experiment described above. (D) Tumor growth (mean ±SD) of HCT-116 and HT-29 colon cancer cells after i.p. treatment (days 10, 15, 20, and 25) with microRNA negative control, antisense-miR-21, antisense-miR-181b-1, or siRNA against STAT3. (E) miR-21, miR-181b-1, and STAT3 mRNA expression levels in colon adenocarcinomas, with each data point representing an individual sample and correlation coefficients (r) indicated. (F) miR-21, miR-181b-1, PTEN, and CYLD mRNA expression levels in colon adenocarcinomas. (G) Model of the inflammatory positive feedback loop that mediates the epigenetic switch between nontransformed and transformed cells. Molecular Cell 2010 39, 493-506DOI: (10.1016/j.molcel.2010.07.023) Copyright © 2010 Elsevier Inc. Terms and Conditions